Marinus Pharmaceuticals Shares Innovative Designs for Epilepsy Treatment
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) has made significant strides in the field of neurological disorders, particularly in its dedication to finding solutions for seizure disorders. This pharmaceutical company has been focused on innovative therapeutic development and will soon be presenting groundbreaking results at the upcoming Neurocritical Care Society (NCS) Annual Meeting.
Important Presentations Scheduled
During the NCS 22nd Annual Meeting, slated for mid-October, Marinus Pharmaceuticals will showcase new findings from the Phase 3 RAISE trial along with meaningful retrospective data concerning patients dealing with status epilepticus. This highlights the company's ongoing commitment to not only advance scientific knowledge but also improve clinical outcomes for patients.
Podium Presentations
On October 17, Marinus will feature a podium presentation at 9:35 a.m. PT, which will delve into crucial insights from a significant study. The title of this presentation is "Efficacy and Safety of Intravenous Ganaxolone for Treatment of Refractory Status Epilepticus: Results from the Phase 3, Double-Blind, Randomized, Placebo-Controlled RAISE Trial." The audience can expect a thorough analysis of the findings and implications for future treatments.
Highlighting Clinical Challenges
In addition to the podium presentation, there will also be a poster presentation on October 16, focusing on interhospital transfer rates in patients experiencing status epilepticus. This session, occurring between 2:45 and 3:45 p.m. PT, will feature a discussion on the challenges healthcare professionals face in managing care for these patients. The title, "High Rate of Interhospital Transfers in Status Epilepticus: Challenges in Management of Care," will be presented by Henrikas Vaitkevicius, M.D., who serves as the Vice President of Clinical Development at Marinus.
About Marinus Pharmaceuticals
Marinus has made huge contributions to the pharmaceutical industry, particularly with its approved product, ZTALMY (ganaxolone) oral suspension. This medication has been a key player in treating seizure disorders since its introduction as an FDA-approved prescription in the U.S. in 2022. Marinus continues to focus on developing innovative solutions that cater to the needs of patients and the medical community.
Engagement and Future Directions
Marinus Pharmaceuticals not only focuses on innovative product development but also actively engages with the scientific community through conferences and presentations. By sharing their findings at premier medical meetings such as the NCS Annual Meeting, they ensure that the latest research reaches medical professionals dedicated to improving patient care.
Frequently Asked Questions
What is the significance of Marinus Pharmaceuticals presenting at the NCS?
The presentations highlight the latest findings in seizure disorder treatments, contributing to the overall understanding of the condition and potential therapies.
What is the RAISE trial?
The RAISE trial is a Phase 3 clinical study investigating the safety and effectiveness of ganaxolone for patients with refractory status epilepticus.
Who will present at the Neurocritical Care Society Annual Meeting?
Brandon Foreman, M.D., will present the podium data, and Henrikas Vaitkevicius, M.D., will lead the poster discussion.
What is ZTALMY?
ZTALMY (ganaxolone) is Marinus Pharmaceuticals' FDA-approved treatment designed specifically for seizure disorders.
Where can further information about Marinus Pharmaceuticals be found?
For more details, visit their website or follow them on social media platforms.
